October 26, 2006 -- Biotech is expecting to be served soon by a new investment vehicle, a collection of 12 ETFs that each target a specific area of focus for biotech companies. A company named Ferghana-Wellspring filed with the SEC to begin marketing the funds. The theory is that investors can select individual areas where they expect better than average growth, whether it be cardiology, infectious diseases, cancer or whatever. We take a look at what we know so far about the new offerings...
